Janux Therapeutics Inc (JANX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Janux Therapeutics Inc (JANX) has a cash flow conversion efficiency ratio of -0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.34 Million) by net assets ($941.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Janux Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Janux Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Janux Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Janux Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Janux Therapeutics Inc ranked by their cash flow conversion efficiency. See how well can Janux Therapeutics Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Lvtong New Energy Electric Vehicle Technology Co. Ltd. Cl A
SHE:301322
|
N/A |
|
JYP Entertainment Corporation
KQ:035900
|
0.025x |
|
Shenzhen Cotran New Material Co Ltd Class A
SHE:300731
|
0.025x |
|
IPERIONX LTD SP.ADR/10
F:30Z0
|
N/A |
|
Lemon Tree Hotels Limited
NSE:LEMONTREE
|
0.113x |
|
Zhuhai Enpower Electric Co Ltd
SHE:300681
|
0.035x |
|
Beijing Join-Cheer Software Co Ltd
SHE:002279
|
0.064x |
|
Zhongtong Bus Holding Co Ltd
SHE:000957
|
0.114x |
Annual Cash Flow Conversion Efficiency for Janux Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Janux Therapeutics Inc from 2019 to 2025. View latest Janux Therapeutics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $956.82 Million | $-82.23 Million | -0.086x | -100.63% |
| 2024-12-31 | $1.02 Billion | $-43.81 Million | -0.043x | +70.83% |
| 2023-12-31 | $344.35 Million | $-50.58 Million | -0.147x | -9.75% |
| 2022-12-31 | $320.74 Million | $-42.92 Million | -0.134x | -188.78% |
| 2021-12-31 | $366.33 Million | $-16.98 Million | -0.046x | -115.53% |
| 2020-12-31 | $-14.64 Million | $-4.37 Million | 0.298x | -38.06% |
| 2019-12-31 | $-7.94 Million | $-3.83 Million | 0.482x | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more